References: Specific therapies for pulmonary hypertension

  • Anderson J, Lavender M, Lau E, Celermajer D, Collins N, Dwyer N, et al. Pharmacological Treatment of Pulmonary Arterial Hypertension in Australia: Current Trends and Challenges. Heart Lung Circ 2020;29(10):1459-68. https://www.ncbi.nlm.nih.gov/pubmed/32280014
  • Atz AM, Adatia I, Wessel DL. Rebound pulmonary hypertension after inhalation of nitric oxide. Ann Thorac Surg 1996;62(6):1759-64. https://www.ncbi.nlm.nih.gov/pubmed/8957383
  • Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334(5):296-301. https://www.ncbi.nlm.nih.gov/pubmed/8532025
  • Fox BD, Shtraichman O, Langleben D, Shimony A, Kramer MR. Combination Therapy for Pulmonary Arterial Hypertension: A Systematic Review and Meta-analysis. Can J Cardiol 2016;32(12):1520-30. https://www.ncbi.nlm.nih.gov/pubmed/27378592
  • Galie N, Channick RN, Frantz RP, Grunig E, Jing ZC, Moiseeva O, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J 2019;53(1). https://www.ncbi.nlm.nih.gov/pubmed/30545971
  • Galie N, Gaine S, Channick R, Coghlan JG, Hoeper MM, Lang IM, et al. Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension. Adv Ther 2022;39(1):796-810. https://www.ncbi.nlm.nih.gov/pubmed/34727317
  • Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016;37(1):67-119. https://www.ncbi.nlm.nih.gov/pubmed/26320113
  • Keogh AM, Jabbour A, Hayward CS, Macdonald PS. Clinical deterioration after sildenafil cessation in patients with pulmonary hypertension. Vasc Health Risk Manag 2008;4(5):1111-3. https://www.ncbi.nlm.nih.gov/pubmed/19183760
  • Klinger JR, Elliott CG, Levine DJ, Bossone E, Duvall L, Fagan K, et al. Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel Report. Chest 2019;155(3):565-86. https://www.ncbi.nlm.nih.gov/pubmed/30660783
  • Lavoie A, Hall JB, Olson DM, Wylam ME. Life-threatening effects of discontinuing inhaled nitric oxide in severe respiratory failure. Am J Respir Crit Care Med 1996;153(6 Pt 1):1985-7. https://www.ncbi.nlm.nih.gov/pubmed/8665066
  • Maron BA. Pulmonary arterial hypertension: Rationale for using multiple vs. single drug therapy. Glob Cardiol Sci Pract 2020;2020(1):e202008. https://www.ncbi.nlm.nih.gov/pubmed/33150152
  • McMullan DM, Bekker JM, Johengen MJ, Hendricks-Munoz K, Gerrets R, Black SM, et al. Inhaled nitric oxide-induced rebound pulmonary hypertension: role for endothelin-1. Am J Physiol Heart Circ Physiol 2001;280(2):H777-85. https://www.ncbi.nlm.nih.gov/pubmed/11158977
  • Spangler ML, Saxena S. Warfarin and bosentan interaction in a patient with pulmonary hypertension secondary to bilateral pulmonary emboli. Clin Ther 2010;32(1):53-6. https://www.ncbi.nlm.nih.gov/pubmed/20171411